Introduction & Objectives
The aim of the study was to assess the EORTC risk tables usefulness in daily urological practice.
Material & Methods
444 patients treated for non-muscle invasive bladder cancer with WL bipolar TURBT were analyzed. After performed WL TURBT using the EORTC scoring system the total score for recurrence and progression for each patient was calculated separately.
Patients were divided into 4 recurrence risk groups. Patients with total recurrence score 0 were classified to group I, 1-4 points to group II, 5-9 to group III, and 10-17 to group IV risk of recurrence. Follow-up and adiuvant therapy were done in according to EAU guidelines.
106 patients (23,8’%) developed recurrent bladder tumour in 12 months of follow-up. Statistical analysis showed statistically relationship between the occurrence of recurrence after one year and recurrence risk groups. The risk of bladder tumour recurrence was statistically higher in intermediate-risk group. The recurrence rate was 0%, 28,6%, 44.7%, and 17,4% in I, II, III and IV recurrence risk group, respectively. About the staging and grading we observed a recurrence rate in PUNMPL group of 3,48%, in pTaLG of 6,55%, in pTaHG of 9,42%, in pT1LG of 1,02 %, in pT1HG of 6,96% and in pCISHG dell’1,84%.
If we evaluate the progression, as an increasing recurrence in staging and grading of the primary lesion but always non-muscle invasive, in the analyzed group within one year occurred in 52 patients (11,7%). The risk of bladder tumour progression was statistically higher in intermediate-risk group. The recurrence rate was 0%, 19,2%, 55.7%, and 25,0% in I, II, III and IV progression risk group, respectively. Stratifying these data for staging (pT) and grading, we observed a progression in the 1,9% of PUNMPL, in the 53,8% of the pTaLG, in the 36,5% of the pTaHG, in the 1,92 % of the pT1LG and in the 7,6% of the pCISHG.
Instead if we consider the progression as the transition to a stage pT2 or more, we observed it in 3 patients 0,67 %, two in the II and one in the other III risk group, both of them in the pTaHG group.
EORTC risk tables are useful to predict the possibility risk of recurrence and progression in patients with non-muscle invasive bladder cancer.